缬沙坦联合氨氯地平治疗老年原发性高血压的临床疗效

目的探讨缬沙坦联合氨氯地平治疗老年原发性高血压疗效及其对血脂的影响。方法选取2009年1月~2011年4月门诊就诊的原发性高血压患者120例,随机分为观察组和对照组,每组各60例,对照组予以氨氯地平治疗,观察组在对照组基础上予以缬沙坦治疗。观察两组治疗前后的血压、血脂的变化。结果观察组的总有效率为95.00%,对照组为80.00%,观察组明显优于对照组差异有统计学意义（P〈0.05）。收缩压（SBP）、舒张压（DBP）和脉压（PP）治疗后较治疗前明显下降（P〈0.01）,而观察组的SBP和PP下降更为明显,差异有统计学意义（P〈0.05或〈0.01）。治疗后总胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）水平观察组较治疗前或者对照组明显降低（P〈0.05）,而高密度脂蛋白胆固醇（HDL-C）水平治疗前后及两组差异无统计学意义（P〉0.05）。两组的不良反应发生率差异无统计学意义（P〉0.05）。结论缬沙坦联合氨氯地平治疗老年原发性高血压疗效确切,对血脂升高具有明显的缓解作用。

Therapeutic effect of valsartan combined with amlodipine on senile patients with primary hypertension and its effects on patients' blood lipids

Objective To observed the therapeutic effect of valsartan combined with amlodipine on senile patients with primary hypertension and its effects on the blood lipids Methods The 120 patients with essential hypertension were, from January 2009 to April 2011,randomly divided into observation group and control group, each consisted of 60 cases. Those in control were treated with amlodipine. Those in observation group were treated the control group plus valsartan. Blood pressure and plasma lipid were observed before and after treatment. Results The total effective rate in the observation group was 95.00% and 80.00% in the control group, showing statistically significant between two groups（P 〈0.05）. The levels of systolic blood pressure （SBP）, diastolic blood pressure （DBP） and pulse pressure （PP） after treatment decreased significantly than that before treatment （P 〈0.01）, while the levels of SBP and PP in observation group decreased more significantly than those in control group P 〈 0.05 or P 〈0.01）. The levels of TC, TG and LDL-C in observation group after treatment decreased significantly than those before treatment or control group （P 〈0.05）, the levels of HDL-C before and after treatment was not statistically significant in two groups（P〉 0.05）. The incidence of adverse reactions showed no significant difference between two groups （P〉 0.05）. Conclusion The efficacy of valsartan combined with amlodipine is effective on senior patients with primary hypertension and can reduce the patients＇ blood lipids